T cell receptor recognizing tumor-associated antigen presented by major histocompatibility complex (TCR (when referring to a specific clonotype, e.g. MAGEA4-specific TCR))

The **T cell receptor recognizing tumor-associated antigen presented by major histocompatibility complex (MHC)** is a heterodimeric membrane protein complex expressed on T cells that binds to peptide antigens derived from tumor proteins when presented by MHC molecules on the surface of target cells. Structurally, the most common TCRs are comprised of α and β polypeptide chains, each featuring variable (V) and constant (C) regions, which provide the antigen-binding site with immense diversity through V(D)J recombination[2][3]. Upon specific recognition of a tumor-associated peptide-MHC complex, the TCR transduces activation signals via associated CD3 signaling molecules containing ITAM motifs, leading to T cell activation, proliferation, cytokine secretion, and cytolytic activity[2][4]. These TCRs are targets for therapeutic engineering, such as TCR-T cell therapies and bispecific molecules, in oncology settings, particularly where the targeted peptide-MHC combination is exclusively or preferentially presented by cancer cells (e.g., MAGEA4 peptide on HLA-A2)[3][7]. Therapeutic targeting is complicated by structural cross-reactivity and the risk of severe immune-mediated toxicities due to recognition of similar peptide-MHC motifs on healthy tissue[3]. The specificity and affinity of TCR-peptide-MHC interactions are key determinants in therapy development and safety[3][4].

Other names

T cell receptor (TCR)tumor-specific TCRantigen-specific TCRTCR recognizing peptide-MHCTCR targeting cancer-testis antigens (e.g. MAGEA4 TCR)

Recognition and binding of tumor-derived peptide-MHC complexes by engineered or expanded T cells, triggering cytotoxicity against tumor cells; Initiation of intracellular signaling leading to T cell activation, cytokine release, and target cell lysis